Novartis and Breckenridge drop cancer drug dispute

10-08-2018

Novartis and Breckenridge drop cancer drug dispute

Novartis and Breckenridge settled their differences over a generic version of Novartis’s cancer drug Afinitor (everolimus) earlier this week.


Novartis, Breckenridge, Afinitor, generics, patent infringement, ANDA, Hatch-Waxman,

LSIPR